ABX474 is a precursor developed in cooperation with the Helmholtz Zentrum Dresden-Rossendorf (HZDR).[1]
It has been used for radiosynthesis of [99mTc]TcO-ABX474 in preclinical and clinical setup following local regulations and guidelines. Results have been published in: Rahbar et al. First Experiences with the new 99mTc labelled PSMA ligand [99mTc]TcO-ABX474 in Patients with Advanced Prostate Cancer Prior to PSMA targeted Radioligand Therapy. Journal of Nuclear Medicine June 2024, 65 (supplement 2), 241711.
[1] Lis et al. Development of [99mTc]TcO-ABX474: Design, Synthesis, and Biological Evaluation of PSMA-Binding Technetium-99m Radioligands for SPECT Imaging of Prostate Cancer. Journal of Medicinal Chemistry 2025, https://doi.org/10.1021/acs.jmedchem.4c02767
Learn more about this compound and send us your request!
It has been used for radiosynthesis of [99mTc]TcO-ABX474 in preclinical and clinical setup following local regulations and guidelines. Results have been published in: Rahbar et al. First Experiences with the new 99mTc labelled PSMA ligand [99mTc]TcO-ABX474 in Patients with Advanced Prostate Cancer Prior to PSMA targeted Radioligand Therapy. Journal of Nuclear Medicine June 2024, 65 (supplement 2), 241711.
[1] Lis et al. Development of [99mTc]TcO-ABX474: Design, Synthesis, and Biological Evaluation of PSMA-Binding Technetium-99m Radioligands for SPECT Imaging of Prostate Cancer. Journal of Medicinal Chemistry 2025, https://doi.org/10.1021/acs.jmedchem.4c02767
Learn more about this compound and send us your request!